🇺🇸 FDA
Pipeline program

KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-3475A

MK-3475A-F11

Phase 2 small_molecule active

Quick answer

KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-3475A for Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials